Company

Trevena, Inc.

Headquarters: Chesterbrook, PA, United States

Employees: 25

CEO: Ms. Carrie L. Bourdow

NASDAQ: TRVN +7.35%

Market Cap

$10.8 Million

USD as of Jan. 1, 2024

Market Cap History

Trevena, Inc. market capitalization over time

Evolution of Trevena, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Trevena, Inc.

Detailed Description

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist that has completed Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.

Top 1-year algo backtest: +284.14%

$10,000 in April 2023 would now be $38,414 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

Trevena, Inc. has the following listings and related stock indices.


Stock: NASDAQ: TRVN wb_incandescent

Stock: FSX: 6T4 wb_incandescent

Key People

Carrie L. Bourdow (President and CEO)

Details

Headquarters:

955 Chesterbrook Boulevard

Suite 110

Chesterbrook, PA 19087

United States

Phone: 610 354 8840